1. Home
  2. BEAM vs KYN Comparison

BEAM vs KYN Comparison

Compare BEAM & KYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • KYN
  • Stock Information
  • Founded
  • BEAM 2017
  • KYN 2004
  • Country
  • BEAM United States
  • KYN United States
  • Employees
  • BEAM N/A
  • KYN N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • KYN Finance/Investors Services
  • Sector
  • BEAM Health Care
  • KYN Finance
  • Exchange
  • BEAM Nasdaq
  • KYN Nasdaq
  • Market Cap
  • BEAM 2.3B
  • KYN 2.2B
  • IPO Year
  • BEAM 2020
  • KYN N/A
  • Fundamental
  • Price
  • BEAM $30.43
  • KYN $12.84
  • Analyst Decision
  • BEAM Buy
  • KYN
  • Analyst Count
  • BEAM 10
  • KYN 0
  • Target Price
  • BEAM $48.75
  • KYN N/A
  • AVG Volume (30 Days)
  • BEAM 1.2M
  • KYN 561.5K
  • Earning Date
  • BEAM 03-04-2025
  • KYN 01-01-0001
  • Dividend Yield
  • BEAM N/A
  • KYN 8.99%
  • EPS Growth
  • BEAM N/A
  • KYN N/A
  • EPS
  • BEAM N/A
  • KYN 0.71
  • Revenue
  • BEAM $349,643,000.00
  • KYN N/A
  • Revenue This Year
  • BEAM N/A
  • KYN N/A
  • Revenue Next Year
  • BEAM $14.62
  • KYN N/A
  • P/E Ratio
  • BEAM N/A
  • KYN $13.79
  • Revenue Growth
  • BEAM 328.73
  • KYN N/A
  • 52 Week Low
  • BEAM $20.84
  • KYN $7.84
  • 52 Week High
  • BEAM $49.50
  • KYN $9.88
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 57.12
  • KYN 42.04
  • Support Level
  • BEAM $25.35
  • KYN $12.78
  • Resistance Level
  • BEAM $35.25
  • KYN $13.12
  • Average True Range (ATR)
  • BEAM 2.10
  • KYN 0.27
  • MACD
  • BEAM 0.56
  • KYN -0.06
  • Stochastic Oscillator
  • BEAM 55.88
  • KYN 9.20

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.

About KYN Kayne Anderson Energy Infrastructure Fund Inc.

Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.

Share on Social Networks: